The Global. A historic milestone for Boehringer Ingelheim that was expected in 2020 and is about to become a reality much sooner than expected. The biopharmaceutical company has reported that after phase III clinical trials on its BI 695501 (adalimumab) molecule, whose original biologic is AbbVie's Humira, it is on the brink of starting the procedures for regulatory approval in key markets such as the United States and Europe.